SCHEMBL23833429

SCHEMBL23833429

COc1ncc(NC(=O)c2cn(C)c3ncccc23)cc1S(=O)(=O)Nc1c(C)cccc1C

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.43
ELANE P08246 2/20 0.41
MALT1 Q9UDY8 2/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
S1PR1 P21453 1/20 0.39
S1PR3 Q99500 1/20 0.39
RXFP1 Q9HBX9 2/20 0.38
GRM4 Q14833 1/20 0.38
PIK3C3 Q8NEB9 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
USP2 O75604 1/20 0.37
BRAF P15056 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30151060 1.00 HTR2C (0.43) HTR2CELANEMALT1MEN1KMT2A
SCHEMBL23840599 0.91 PIK3C3 (0.36) HTR2CMALT1MEN1KMT2ARXFP1
SCHEMBL30150995 0.87 MAPT (0.46) HTR2CMALT1MEN1KMT2AS1PR1
SCHEMBL23833490 0.87 MAPT (0.46) HTR2CMALT1MEN1KMT2AS1PR1
SCHEMBL25754534 0.87 MEN1 (0.49) HTR2CMEN1KMT2AS1PR1S1PR3
SCHEMBL23840623 0.85 KMT2A (0.44) MEN1KMT2ARXFP1GRM4PIK3C3
SCHEMBL23840611 0.82 NAMPT (0.49) MEN1KMT2AGRM4PIK3C3POLB
SCHEMBL25485494 0.82 KCNK3 (0.52) MEN1KMT2ARXFP1POLBGAA
SCHEMBL23840465 0.81 NAMPT (0.49) MEN1KMT2ARXFP1PIK3C3POLB
SCHEMBL25487581 0.81 NPC1 (0.45) MALT1MEN1KMT2APIK3C3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121030-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D HTR2C 3869/4885ELANE 4038/4885MALT1 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.